<!DOCTYPE html>
<html lang="en">
<head>
<meta charset="UTF-8">
<meta name="viewport" content="width=device-width, initial-scale=1.0">
<title>Diabetes Mellitus Reference</title>
<style>
  body { font-family: Arial, sans-serif; line-height: 1.6; margin: 20px; color: #333; background-color: #f9f9f9; }
  h1, h2, h3 { color: #007acc; }
  h1 { text-align: center; }
  .toc { background: #eef; padding: 10px; border-left: 4px solid #007acc; margin-bottom: 20px; }
  .toc a { text-decoration: none; display: block; color: #007acc; margin: 4px 0; }
  section { margin-bottom: 40px; }
</style>
</head>
<body>

<h1>📘 Diabetes Mellitus – Evidence-Based Reference</h1>
<p style="text-align:center; color:#777;">Based on ADA, ISPAD, and AMBOSS Guidelines</p>

<div class="toc">
  <h3>📑 Table of Contents</h3>
  <a href="#summary">Summary</a>
  <a href="#types">Types & Comparison</a>
  <a href="#epidemiology">Epidemiology</a>
  <a href="#etiology">Etiology</a>
  <a href="#clinical">Clinical Features</a>
  <a href="#screening">Screening & Diagnosis</a>
  <a href="#management">Management</a>
  <a href="#complications">Complications</a>
  <a href="#children">Children & Special Groups</a>
</div>

<section id="summary">
  <h2>🔷 Summary</h2>
  <p>Diabetes mellitus (DM) is a group of metabolic diseases characterized by chronic hyperglycemia. <b>Type 1</b> is autoimmune, with absolute insulin deficiency. <b>Type 2</b> involves insulin resistance with relative deficiency, strongly linked to obesity and lifestyle. Diagnosis is based on glucose or HbA1c levels, and management is comprehensive, addressing glycemic control and associated risks.</p>
</section>

<section id="types">
  <h2>🔷 Types & Comparison</h2>
  <p><b>Type 1 DM:</b> Autoimmune β-cell destruction, usually childhood onset, high risk of ketoacidosis. Requires insulin.</p>
  <p><b>Type 2 DM:</b> Insulin resistance & β-cell dysfunction, adult onset, often asymptomatic. Managed with lifestyle, oral agents, and possibly insulin.</p>
</section>

<section id="epidemiology">
  <h2>🔷 Epidemiology</h2>
  <p>T1DM: ~5-10% of diabetics, peak at 4–6 & 10–14 years, more common in Whites. <br>
     T2DM: ~90%, increasing prevalence, more common in older adults, certain minorities (Native American, Hispanic, African American, Asian).</p>
</section>

<section id="etiology">
  <h2>🔷 Etiology</h2>
  <p>T1DM: HLA-DR3/DR4 positive, linked to other autoimmune diseases (e.g., Hashimoto).<br>
     T2DM: Risk factors include obesity, sedentary lifestyle, family history, high-risk ethnicity, and certain medications (e.g., glucocorticoids).</p>
</section>

<section id="clinical">
  <h2>🔷 Clinical Features</h2>
  <p><b>Classic hyperglycemia symptoms:</b> Polyuria, polydipsia, polyphagia, weight loss. T1DM often acute; T2DM gradual and often asymptomatic.</p>
</section>

<section id="screening">
  <h2>🔷 Screening & Diagnosis</h2>
  <p>Recommended for high-risk individuals (age ≥35, obesity + risk factors). Diagnostic tests: FPG ≥126 mg/dL, HbA1c ≥6.5%, OGTT ≥200 mg/dL, or random glucose ≥200 mg/dL with symptoms.</p>
</section>

<section id="management">
  <h2>🔷 Management</h2>
  <p>Goals: Achieve and maintain glycemic targets while minimizing hypoglycemia. Key components:</p>
  <ul>
    <li>🩺 Lifestyle: diet, exercise, smoking cessation.</li>
    <li>💊 Medications: Metformin first-line for T2DM. Insulin for T1DM and advanced T2DM. Consider GLP-1RA, SGLT2i, DPP-4i, TZDs based on comorbidities.</li>
    <li>🏥 Monitoring: HbA1c every 3–6 months, annual microvascular screening (retina, kidney, neuropathy).</li>
    <li>❤️ ASCVD risk reduction: statins, ACEi/ARB, antiplatelet if indicated.</li>
  </ul>
</section>

<section id="complications">
  <h2>🔷 Complications</h2>
  <p>Acute: DKA, HHS, severe hypoglycemia. <br>
     Chronic: Microvascular (retinopathy, nephropathy, neuropathy), macrovascular (CAD, stroke, PAD), diabetic foot, infections.</p>
</section>

<section id="children">
  <h2>🔷 Children & Special Groups</h2>
  <p>Children with T1DM need insulin therapy and psychosocial support. T2DM in children is rising; treat with metformin/insulin if >10 years. Screen for thyroid, celiac disease, dyslipidemia, mental health.</p>
</section>

<footer>
  <p style="font-size: 0.8em; color: #777; text-align: center;">Sources: ADA 2025, ISPAD, AMBOSS. Last updated: 2025.</p>
</footer>

</body>
</html>
